Interferon-α Therapy and Anti-Human Leukocyte Antigen Antibodies in Hepatitis C Virus-Positive Patient: Case Report

C. Cervelli, G. Fontecchio, M. A. Fioroni, R. Azzarone, C. Battistoni, D. Maccarone, F. Pisani, F. Papola

Research output: Contribution to journalArticle

Abstract

Interferon-alpha (IFN-α) is currently the only treatment for patients with chronic hepatitis C. Yet it can induce acute renal transplantation rejection possibly by stimulating humoral responses. We tested patient sera for detection of donor-specific anti-human leukocyte antigen (HLA) antibodies observing an increased panel-reactive antibodies value after IFN-α therapy. Then, we also investigated whether antiviral treatment with IFN-α was related to an increased and/or different production of class I and class II anti-HLA antibodies. Patient sera analysis performed by a cytofluorimetric method using flow PRA tests showed the appearance of new HLA-antibody specificities. This study underlined that INF-α therapy modifies a patient's immune profile; hence, it is recommended to confirm HLA-antibody specificities after treatment in order to protect recipients from enhanced rejection risk owing to a false-negative donor-specific cross-match.

Original languageEnglish
Pages (from-to)2040-2041
Number of pages2
JournalTransplantation Proceedings
Volume39
Issue number6
DOIs
Publication statusPublished - Jul 2007

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Fingerprint Dive into the research topics of 'Interferon-α Therapy and Anti-Human Leukocyte Antigen Antibodies in Hepatitis C Virus-Positive Patient: Case Report'. Together they form a unique fingerprint.

Cite this